Meet our team of experienced subject
matter experts.

We prioritize transparency, swift communication, and competent guidance. Our commitment to excellence ensures that our clients receive informed support and achieve their objectives efficiently.

Find us at a conference
alt=""

Meet our team of experienced subject matter experts.

We prioritize transparency, swift communication, and competent guidance. Our commitment to excellence ensures that our clients receive informed support and achieve their objectives efficiently.

Find us at a conference
alt=""
alt=""

Meet our team of experienced subject matter experts.

We prioritize transparency, swift communication, and competent guidance. Our commitment to excellence ensures that our clients receive informed support and achieve their objectives efficiently.

Find us at a conference

Pascal Winnen (MSc)
Chief Executive Officer/
Quality Assurance/
Board of Directors

Mohamed Hussien (BPharm, PhD)
Chief Commercial Officer/
Neuroscience

Maria Kuthning (MSc)
Head of Clinical Operations

Cornelia Baumgartner- Diolaiuti
Clinical Operations Expert/
Oncology

Gheorghe Nicusor Pop (Dr. Med)
Biostatician/
Medical Monitor

Sandra Müller Lettlova (PhD)
Clinical Trial Manager/
Clinical Scientist

Ossama Khalaf (BPharm, PhD)
Medical writer/
Grant Expert

Franziska Stemmler
Business Development

Gabriela Wesolowski
Sales

Frank Stein (Prof. Dr. Dr. h.c.)
Senior Expert Quality &
Regulatory Affairs Medical Devices

Dr. Frank Kramer
Clinical Operations Expert Cardiology

João Bocas
Wearable Devices Expert

Clive Roper (BSc, PhD, CBiol, CSci, ERT, FRSB)
Toxicology Expert

Cátia Moutinho
Medical Writer/
Single-Cell Technology

Dr. Thorben Bonarius
Regulatory Affairs Expert Pharma- & Biotech

Lucie Pribylova (MSc)
Administration

Ivana Krešić
Digital Media

Juan Ruiz (MFA)
Graphic Design

Dr. Arthur Redpath (BVM&S MRCVS MCIM)
Animal Health Business Development Leader

Dr. Stefan Stübinger
Innovation & Medical Advisor Cranio-Maxillofacial and Detal implant Expert

David Ochoa Soto
Intern

Paul Hadvary (Dr. scnat ETH)
Chairman/
Board of Directors

Ricardo Cordero (Dr. oec HSG)
Board of Directors

Peter Huber
Board of Directors

Ralf Schumacher
Board of Directors

Pascal Winnen (MSc)
Chief Executive Officer/
Quality Assurance/
Board of Directors

Mohamed Hussien (BPharm, PhD)
Chief Commercial Officer/
Neuroscience

Maria Kuthning (MSc)
Head of Clinical Operations

Cornelia Baumgartner- Diolaiuti
Clinical Operations Expert/
Oncology

Gheorghe Nicusor Pop (Dr Med)
Biostatician/
Medical Monitor

Sandra Lettlova
Clinical Trial Manager/
Clinical Scientist

Ossama Khalaf (BPharm, PhD)
Medical writer/
Grant Expert

Franziska Stemmler
Business Development

Gabriela Wesolowski
Sales

Frank Stein (Prof. Dr. Dr. h.c.)
Senior Expert Quality &
Regulatory Affairs Medical Devices

Dr. Frank Kramer
Clinical Operations Expert Cardiology

João Bocas
Wearable Devices Expert

Clive Roper (BSc, PhD, CBiol, CSci, ERT, FRSB)
Toxicology Expert

Cátia Moutinho
Medical Writer/
Single-Cell Technology

Dr. Thorben Bonarius
Regulatory Affairs Expert Pharma- & Biotech

Lucie Pribylova (MSc)
Administration

Ivana Krešić
Digital Media

Juan Ruiz (MFA)
Graphic Design

Dr. Arthur Redpath (BVM&S MRCVS MCIM)
Animal Health Business Development Leader

Dr. Stefan Stüberinger
Innovation & Medical Advisor Cranio-Maxillofacial and Detal implant Expert

David Ochoa Soto
Intern

Paul Hadvary (Dr. scnat ETH)
Chairman/
Board of Directors

Ricardo Cordero (Dr. oec HSG)
Board of Directors

Peter Huber
Board of Directors

Ralf Schumacher
Board of Directors

Pascal Winnen (MSc)
Chief Executive Officer/
Quality Assurance/
Board of Directors

Mohamed Hussien (BPharm, PhD)
Chief Commercial Officer/
Neuroscience

Cornelia Baumgartner- Diolaiuti
Clinical Operations Expert/
Oncology

Gheorghe Nicusor Pop (Dr. Med)
Biostatician/
Medical Monitor

Maria Kuthning (MSc)
Head of Clinical Operations

Sandra Müller Lettlova (PhD)
Clinical Trial Manager/
Clinical Scientist

Ossama Khalaf (BPharm, PhD)
Medical writer/
Grant Expert

Franziska Stemmler
Business Development

Gabriela Wesolowski
Sales

Frank Stein (Prof. Dr. Dr. h.c.)
Senior Expert Quality &
Regulatory Affairs Medical Devices

Dr. Frank Kramer
Clinical Operations Expert Cardiology

João Bocas
Wearable Devices Expert

Clive Roper (BSc, PhD, CBiol, CSci, ERT, FRSB)
Toxicology Expert

Cátia Moutinho
Medical Writer/
Single-Cell Technology

Dr. Thorben Bonarius
Regulatory Affairs Expert Pharma- & Biotech

Lucie Pribylova (MSc)
Administration

Ivana Krešić
Digital Media

Juan Ruiz (MFA)
Graphic Design

Dr. Arthur Redpath (BVM&S MRCVS MCIM)
Animal Health Business Development Leader

Dr. Stefan Stübinger
Innovation & Medical Advisor Cranio-Maxillofacial and Detal implant Expert

David Ochoa Soto
Intern

Paul Hadvary (Dr. scnat ETH)
Chairman/
Board of Directors

Ricardo Cordero (Dr. oec HSG)
Board of Directors

Peter Huber
Board of Directors

Ralf Schumacher
Board of Directors

Meet us at the following conferences

8th AMR Conference
Novel Antimicrobials & AMR Diagnostics

6-7 March 2024
Basel, Switzerland

Event website

Join me there

Franziska Stemmler,
Business Development

Swiss Nordic Bio 2024
Connecting Healthcare, Investors and Industry 

7 March 2024
Zürich, Switzerland

Event website

Join me there

Mohamed Hussein,
Chief Commercial Officer

BIO-Europe Spring
Europe’s Largest Springtime Biotech Partnering Event

18 – 20 March 2024
Barcelona, Spain

Event website

Join me there

Mohamed Hussein,
Chief Commercial Officer

MedTech Meetup 2024
The Belgian MedTech industry in the spotligh

14 March 2024
Brussels, Belgium

Event website

Join me there

Mohamed Hussein,
Chief Commercial Officer

Meet us at the following conferences

8th AMR Conference
Novel Antimicrobials & AMR Diagnostics

6-7 March 2024
Basel, Switzerland

Visit event website

Join me there

Franziska Stemmler,
Business Development

Swiss Nordic Bio 2024
Connecting Healthcare, Investors and Industry 

7 March 2024
Zürich, Switzerland

Visit event website

Join me there

Mohamed Hussein,
Chief Commercial Officer

BIO-Europe Spring
Europe’s Largest Springtime Biotech Partnering Event

18 – 20 March 2024
Barcelona, Spain

Visit event website

Join me there

Mohamed Hussein,
Chief Commercial Officer

MedTech Meetup 2024
The Belgian MedTech industry in the spotligh

14 March 2024
Brussels, Belgium

Visit event website

Join me there

Mohamed Hussein,
Chief Commercial Officer

HEMEX in the media

Convince investors of innovations

At HEMEX, startups receive a podium to present their advanced health care innovations to potential investors in detail and in a small group. From the implant system for the treatment of chronic lymphedema swelling to the method for self-measurement of sleep disorders and therapy for patients with multi-resistant cancers to the technology for combating the causes of periodontitis – four promising young companies took part in the first physical pitch event last year since the outbreak of the pandemic Liestal took part and asked critical questions.

HEMEX receives CHF 7.1 million

HEMEX, partner of the Basel Area Business & Innovation, wants to use the fresh capital to finance initial investments in the early phase of start-ups that are active in the life sciences. The Liestal-based company also plans to recruit new team members for clinical activities, quality assurance and regulatory affairs.

EIC Pathfinder beneficiary HEMEX completes a €6.8 million Series C round

HEMEX, an EIC Pathfinder beneficiary company, has completed another fundraising round. After the first closing in February 2021, they secured a Series C round, increasing the amount to approximately €6.8 million (CHF 7.1 million).

HEMEX banks 7.1 million Swiss Francs

Hemex has raised a total of 7.1 million Swiss francs as part of a Series C financing round. The company for clinical contract research and investments in start-ups intends to finance firms in their early phase in addition to supporting plans aimed at hiring new team members.

HEMEX attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for HEMEX. The biotech incubator will use the funds to accelerate its global expansion.

HEMEX in the media

Convince investors of innovations

At HEMEX, startups receive a podium to present their advanced health care innovations to potential investors in detail and in a small group. From the implant system for the treatment of chronic lymphedema swelling to the method for self-measurement of sleep disorders and therapy for patients with multi-resistant cancers to the technology for combating the causes of periodontitis – four promising young companies took part in the first physical pitch event last year since the outbreak of the pandemic Liestal took part and asked critical questions.

HEMEX receives CHF 7.1 million

HEMEX, partner of the Basel Area Business & Innovation, wants to use the fresh capital to finance initial investments in the early phase of start-ups that are active in the life sciences. The Liestal-based company also plans to recruit new team members for clinical activities, quality assurance and regulatory affairs.

EIC Pathfinder beneficiary HEMEX completes a €6.8 million Series C round

HEMEX, an EIC Pathfinder beneficiary company, has completed another fundraising round. After the first closing in February 2021, they secured a Series C round, increasing the amount to approximately €6.8 million (CHF 7.1 million).

HEMEX banks 7.1 million Swiss Francs

Hemex has raised a total of 7.1 million Swiss francs as part of a Series C financing round. The company for clinical contract research and investments in start-ups intends to finance firms in their early phase in addition to supporting plans aimed at hiring new team members.

HEMEX attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for HEMEX. The biotech incubator will use the funds to accelerate its global expansion.

HEMEX in the media

Convince investors of innovations

At HEMEX, startups receive a podium to present their advanced health care innovations to potential investors in detail and in a small group. From the implant system for the treatment of chronic lymphedema swelling to the method for self-measurement of sleep disorders and therapy for patients with multi-resistant cancers to the technology for combating the causes of periodontitis – four promising young companies took part in the first physical pitch event last year since the outbreak of the pandemic Liestal took part and asked critical questions.

HEMEX receives CHF 7.1 million

HEMEX, partner of the Basel Area Business & Innovation, wants to use the fresh capital to finance initial investments in the early phase of start-ups that are active in the life sciences. The Liestal-based company also plans to recruit new team members for clinical activities, quality assurance and regulatory affairs.

EIC Pathfinder beneficiary HEMEX completes a €6.8 million Series C round

HEMEX, an EIC Pathfinder beneficiary company, has completed another fundraising round. After the first closing in February 2021, they secured a Series C round, increasing the amount to approximately €6.8 million (CHF 7.1 million).

HEMEX banks 7.1 million Swiss Francs

Hemex has raised a total of 7.1 million Swiss francs as part of a Series C financing round. The company for clinical contract research and investments in start-ups intends to finance firms in their early phase in addition to supporting plans aimed at hiring new team members.

HEMEX attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for HEMEX. The biotech incubator will use the funds to accelerate its global expansion.